EZH2 and systemic lupus erythematosus: Therefore, relatively lower dose and less frequent regimen may be better for the treatment of SLE with EZH2 inhibitor, which is different from the treatment of tumors, as it has been shown that less frequent dosing regimen and relatively short half-life of GSK126 limited the effective exposure (48).